Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$74.46 USD

74.46
1,955,806

-0.13 (-0.17%)

Updated Aug 5, 2025 02:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Clovis (CLVS) witnessed narrower year-over-year loss in the third quarter. Also, the company's revenues missed estimates. Rubraca adoption slower.

    Zacks Equity Research

    Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal

    by Zacks Equity Research

    Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.

      Zacks Equity Research

      Merck (MRK) Q3 Earnings Top, Sales Lag, Keytruda Stays Strong

      by Zacks Equity Research

      Merck (MRK) beat estimates for earnings but missed the same for sales in Q3. Despite the sales miss, Merck raised its adjusted earnings guidance for 2017 while increasing its sales guidance marginally.

        Zacks Equity Research

        Celgene (CELG) Tops Q3 Earnings, Sales Miss, Updates View

        by Zacks Equity Research

        Celgene (CELG) beats third-quarter 2017 earnings estimates on the back of robust Revlimid performance.

          Zacks Equity Research

          Celgene Down on Discontinued Crohn's Disease Drug Study

          by Zacks Equity Research

          Shares of Celgene Corporation (CELG) declined after the company announced that a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn's disease and the extension trial, SUSTAIN (CD-004) will be discontinued.

            Zacks Equity Research

            Cancer Treatment Update: Second Gene Therapy Receives Approval

            by Zacks Equity Research

            The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.

              Zacks Equity Research

              AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review

              by Zacks Equity Research

              AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.

                Zacks Equity Research

                Bristol-Myers Gets Priority Review for Opdivo Label Expansion

                by Zacks Equity Research

                Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.

                  Zacks Equity Research

                  Valeant Reports Positive Results on Psoriasis Drug Siliq

                  by Zacks Equity Research

                  Valeant Pharmaceuticals International, Inc. (VRX) announced encouraging results from the long-term phase III extension study, AMAGINE-2 on psoriasis drug Siliq.

                    Zacks Equity Research

                    Cancer Space Update: Lung & Breast Cancer Studies in Focus

                    by Zacks Equity Research

                    While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

                      Zacks Equity Research

                      Lilly's Verzenio Gets Priority Review in First-Line Setting

                      by Zacks Equity Research

                      Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.

                        Zacks Equity Research

                        Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca

                        by Zacks Equity Research

                        Clovis submitted a sNDA to the FDA for expansion of Rubraca's label in maintenance treatment for ovarian cancer patients who are in a partial or complete response to platinum-based chemotherapy.

                          Zacks Equity Research

                          Agilent Boosts Market Share With FDA Nod to New Cancer Test

                          by Zacks Equity Research

                          Agilent Technologies' (A) recent FDA approval for a cancer diagnostic, PD-L1 IHC 28-8 pharmDx for UC and SCCHN patients will further expand its share in the growing cancer-diagnostic market.

                            Zacks Equity Research

                            Nektar's Lead Drugs Drive Growth, Partner Reliance a Woe

                            by Zacks Equity Research

                            Nektar (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.

                              Zacks Equity Research

                              AstraZeneca's Bevespi Improves Lung Function in Phase III Study

                              by Zacks Equity Research

                              AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.

                                Zacks Equity Research

                                Allergan Authorizes New $2B Share Buyback Plan, Stock Up

                                by Zacks Equity Research

                                Allergan plc (AZN) sanctions a new stock repurchase program. The company also reiterates its commitment toward annual hike of quarterly cash dividend.

                                  Zacks Equity Research

                                  Allergan's (AGN) Vraylar Gets RTF From FDA, New Data for CVC

                                  by Zacks Equity Research

                                  The FDA slaps a refusal-to-file letter on Allergan's (AGN) Vraylar for its supplemental New Drug Application. The company tries to expand the drug???s label for its use as a maintenance treatment.

                                    Zacks Equity Research

                                    Bristol-Myers (BMY) Opdivo Gets Approval for Liver Cancer

                                    by Zacks Equity Research

                                    Bristol-Myers Squibb Company (BMY) announced that the FDA has approved immuno-oncology drug Opdivo for liver cancer.

                                      Zacks Equity Research

                                      Juno Tenders $250M Follow-on Public Offering of Common Stock

                                      by Zacks Equity Research

                                      Juno Therapeutics (JUNO) launches a proposed follow-on public offering of shares. The company plans to utilize net proceeds from the offering for general corporate purposes.

                                        Zacks Equity Research

                                        Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval

                                        by Zacks Equity Research

                                        Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.

                                          Zacks Equity Research

                                          Implied Volatility Surging for AstraZeneca (AZN) Stock Options

                                          by Zacks Equity Research

                                          AstraZeneca (AZN) needs Investors to pay close attention to the stock based on moves in the options market lately.

                                            Zacks Equity Research

                                            TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion

                                            by Zacks Equity Research

                                            TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.

                                              Zacks Equity Research

                                              Oncology Space in Focus this Week on ESMO Presentations

                                              by Zacks Equity Research

                                              There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.

                                                Zacks Equity Research

                                                AstraZeneca Sells Remaining Rights to its Anaesthetics Drugs

                                                by Zacks Equity Research

                                                AstraZeneca (AZN) recently sold its remaining rights to its anaesthetics medicines to Aspen Group for an upfront consideration of $555 million.

                                                  Zacks Equity Research

                                                  Bristol-Myers Reports Positive Results from Melanoma Study

                                                  by Zacks Equity Research

                                                  Bristol-Myers Squibb Company (BMY) announced encouraging results from a phase III study, CheckMate -238, on Opdivo.